{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:16:31Z","timestamp":1788682591390,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,15]]},"DOI":"10.1097\/qad.0b013e328345ef5e","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T03:20:57Z","timestamp":1298431257000},"page":"1051-1056","source":"Crossref","is-referenced-by-count":22,"title":["Managing hepatitis B\/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil\/emtricitabine) experienced patients"],"prefix":"10.1097","volume":"25","author":[{"given":"Libu\u0161e","family":"Ratcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael BJ","family":"Beadsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J","family":"Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"R2-5-20210130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"key":"R3-5-20210130","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1097\/QAD.0b013e32832e463a","article-title":"Hepatitis B and long-term HIV outcomes in coinfected HAART recipients","volume":"23","author":"Hoffmann","year":"2009","journal-title":"AIDS"},{"key":"R4-5-20210130","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1086\/599110","article-title":"Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis","volume":"48","author":"Nikolopoulos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R5-5-20210130","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"R6-5-20210130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1468-1293.2008.00564.x","article-title":"Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study","volume":"9","author":"Omland","year":"2008","journal-title":"HIV Med"},{"key":"R7-5-20210130","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1086\/525857","article-title":"Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine","volume":"46","author":"Guti\u00e9rrez","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R8-5-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/135965350701200201","article-title":"Reversibility of cirrhosis in HIV\/HBV coinfection","volume":"12","author":"Mallet","year":"2007","journal-title":"Antivir Ther"},{"key":"R9-5-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/135965350701200116","article-title":"Improvements in parameters of end-stage liver disease in patients with HIV\/HBV-related cirrhosis treated with tenofovir","volume":"12","author":"Matthews","year":"2007","journal-title":"Antivir Ther"},{"key":"R10-5-20210130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults","volume":"9","author":"Rockstroh","year":"2008","journal-title":"HIV Med"},{"key":"R11-5-20210130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008","volume":"9","author":"Gazzard","year":"2008","journal-title":"HIV Med"},{"key":"R12-5-20210130","first-page":"227","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis Br J H","volume":"50","year":"2009","journal-title":"epatol"},{"key":"R13-5-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2009.00781.x","article-title":"British HIV Association guidelines for the management of coinfection with HIV-1 and chronic hepatitis B or C virus 2010","volume":"11","author":"Brook","year":"2010","journal-title":"HIV Med"},{"key":"R14-5-20210130","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","article-title":"Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients","volume":"133","author":"Lampertico","year":"2007","journal-title":"Gastroenterology"},{"key":"R15-5-20210130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1468-1293.2008.00683.x","article-title":"Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort","volume":"10","author":"Alvarez-Uria","year":"2009","journal-title":"HIV Med"},{"key":"R16-5-20210130","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/01.aids.0000247116.89455.5d","article-title":"Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection","volume":"20","author":"Schmutz","year":"2006","journal-title":"AIDS"},{"key":"R17-5-20210130","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/QAD.0b013e32832b43f2","article-title":"Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV\/HBV coinfected individuals","volume":"23","author":"Matthews","year":"2009","journal-title":"AIDS"},{"key":"R18-5-20210130","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"R19-5-20210130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-5-20210130","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1872-034X.2008.00332.x","article-title":"A case of HIV co-infected with hepatitis B virus precore\/core deletion mutant treated by entecavir","volume":"38","author":"Fukushima","year":"2008","journal-title":"Hepatol Res"},{"key":"R21-5-20210130","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/QAD.0b013e3282ffde91","article-title":"The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients","volume":"22","author":"Sasadeusz","year":"2008","journal-title":"AIDS"},{"key":"R22-5-20210130","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1086\/587174","article-title":"Entecavir therapy induces de novo HIV reverse-transcriptase M184 V mutation in an antiretroviral therapy-naive patient","volume":"46","author":"Jakobsen","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R23-5-20210130","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1097\/QAD.0b013e32830b3ab5","article-title":"Efficacy and safety of entecavir for chronic HBV in HIV\/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy","volume":"22","author":"Pess\u00f4a","year":"2008","journal-title":"AIDS"},{"key":"R27-5-20210130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095632020901900404","article-title":"Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside\/nucleotide analogues","volume":"19","author":"Zhu","year":"2009","journal-title":"Antivir Chem Chemother"},{"key":"R30-5-20210130","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1572-0241.2006.00647.x","article-title":"Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study","volume":"101","author":"Chen","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R31-5-20210130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/jhep.2001.27563","article-title":"Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy","volume":"34","author":"Yuen","year":"2001","journal-title":"Hepatology"},{"issue":"Suppl 10","key":"R32-5-20210130","first-page":"232A","article-title":"Maximal early HBV suppression is predictive of Optimal virologic and clinical efficacy in Nucleoside-treated hepatitis B patients: Scientific observations from a large Multinational trial (the Globe study)","volume":"42","author":"Lai","year":"2005","journal-title":"Hepatology"},{"key":"R33-5-20210130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.21939","article-title":"Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response","volume":"46","author":"Yuen","year":"2007","journal-title":"Hepatology"},{"key":"R34-5-20210130","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2008.05455.x","article-title":"Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients","volume":"23","author":"Suzuki","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R35-5-20210130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201105150-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:50:07Z","timestamp":1786042207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201105150-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,15]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328345ef5e","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,15]]}}}